CM
CLSD

Crestline Management’s Clearside Biomedical CLSD Stock Holding History

Crestline Management’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-8,443
Closed -$1.35M – 165
2018
Q2 		$1.35M Buy
8,443
+1,332
+19% +$225K 0.14% 174
2018
Q1 		$1.15M Buy
+7,111
New +$866K 0.14% 134

Other funds holding CLSD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Crestline Management's CLSD Position: Q3 2018 in Review

Crestline Management sold out of Clearside Biomedical (CLSD) in Q3 2018, closing a stake of 8,443 shares — an estimated $1.35M sold.

Crestline Management first reported a position in CLSD in Q1 2018 and held it in 2 quarters. The position peaked at $1.35M in Q2 2018. 89 funds tracked by Wall St. Rank hold CLSD as of Q3 2018.

  • Crestline Management reported no remaining Clearside Biomedical position as of Q3 2018 after selling out during the quarter.
  • Crestline Management sold 8,443 Clearside Biomedical shares in Q3 2018, an estimated $1.35M.
  • Crestline Management first reported a position in Clearside Biomedical in Q1 2018 and held it in 2 quarters.
  • Crestline Management's Clearside Biomedical position peaked at $1.35M in Q2 2018.
  • 89 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2018.

Based on Crestline Management's 13F filing for Q3 2018, filed 14 Nov 2018.